Face transplantation

Face transplantation is a reconstructive surgical procedure in which all or part of a person's face is replaced with facial tissue recovered from a deceased donor, in order to restore form and function after severe disfigurement that cannot be repaired by conventional reconstruction [1][2]. The transplanted tissue is a single, blood-supplied unit that may include skin, subcutaneous fat, muscle, blood vessels, nerves, cartilage, and, in more extensive grafts, bone such as the jaws, cheekbones, and palate [3][4]. Because it transfers multiple tissue types as one vascularized structural unit rather than a single solid organ, face transplantation is classified as a form of vascularized composite allotransplantation (VCA), and it shares core challenges with other VCA procedures such as hand transplantation, including allograft rejection and the burden of lifelong immunosuppression [1][2][5].

Face transplantation is generally not a life-saving operation; its aim is to improve quality of life, appearance, and functions such as breathing, eating, speaking, and facial expression [6][7]. The first partial face transplant was performed in Amiens, France, in 2005, and as of a study covering procedures through September 2023, approximately 50 face transplants had been performed worldwide at 18 centers in 11 countries [8][9].

Classification as a vascularized composite allograft

A face transplant is a vascularized composite allograft (VCA), defined in U.S. regulation as a body part that is vascularized and requires surgical reconnection of blood vessels to function, contains multiple tissue types, and is recovered from a donor and transplanted into a recipient as a single anatomical unit [10]. VCAs are distinguished from solid-organ transplants (such as those discussed in organ transplantation) by their inclusion of skin, which is among the most immunogenic of transplanted tissues and a frequent target of rejection [2][5].

In the United States, VCAs, including faces, were added to the definition of "covered human organs" under the Organ Procurement and Transplantation Network (OPTN) Final Rule effective July 3, 2014, placing their procurement and transplantation under the oversight of the OPTN and the Health Resources and Services Administration (HRSA) within the Department of Health and Human Services [10][11].

Partial versus full face transplantation

Face transplants are commonly divided into partial and full (total) procedures. A partial face transplant replaces specific aesthetic and functional subunits, such as the nose, lips, and chin, while leaving unaffected regions intact [12][8]. A full or total face transplant replaces essentially the entire facial surface and may include the complete facial skin and musculature, nose, lips, eyelids, and underlying bony structures such as the maxilla (upper jaw), mandible (lower jaw), cheekbones, palate, and teeth [13][14]. The world's first partial face transplant (2005) involved the nose, lips, and chin, whereas the first full face transplant (2010) included the complete facial skin and musculature along with the nose, lips, jaws, cheekbones, palate, and teeth [12][13][14].

Indications

Face transplantation is considered for patients with extensive facial disfigurement that cannot be adequately treated by autologous (the patient's own tissue) reconstructive surgery [1][6]. Reported causes leading to facial VCA include trauma, burns and explosion or blast injuries, ballistic (gunshot) injuries, animal attacks, infection, and tumors or their resection [1][15][12]. In one analysis of VCA procedures, trauma was the leading underlying cause, followed by infection and burn or explosion injuries [15]. The first recorded face transplant recipient had been disfigured by a dog attack, and the first U.S. recipient had been injured by a close-range shotgun blast [12][16].

Candidate patients typically have defects involving central facial structures, such as the nose, lips, and eyelids, that are difficult to reconstruct with conventional flaps and that impair both appearance and essential functions including breathing, eating, and speech [6][7].

Recipient selection

Selection of face transplant candidates involves multidisciplinary evaluation that weighs the severity of the defect, the likelihood of functional and aesthetic benefit, and the patient's ability to tolerate lifelong immunosuppression [1][6]. Candidates are generally adults in otherwise good health whose disfigurement cannot be repaired by standard plastic or reconstructive surgery and who can reliably take immunosuppressive medication indefinitely [6].

Psychological and psychosocial screening is a central component of selection, assessing motivation, expectations, capacity to adhere to a demanding medication and follow-up regimen, and the ability to adjust to a new facial appearance [6][2]. Immunosuppression candidacy is also assessed, since active infection, certain malignancies, and conditions that would make long-term immunosuppression unsafe can be contraindications [6][17]. Because non-adherence to immunosuppression has been associated with graft loss and death, demonstrated reliability and adequate psychosocial support are emphasized [9][8].

The surgical procedure

A face transplant transfers a donor facial allograft as a vascularized unit. Depending on the defect, the allograft may include skin, subcutaneous fat, muscles of facial expression, sensory and motor nerves, arteries and veins, cartilage, and bone such as portions of the maxilla and mandible [3][4][13]. The recovered tissue is connected to the recipient by microsurgical anastomosis of arteries and veins to restore blood flow, coaptation (joining) of nerves to enable return of sensation and movement, and fixation of any bony components, followed by layered repair of muscle, mucosa, and skin [3][13][2].

These are among the most complex reconstructive operations performed, frequently lasting many hours and requiring large multidisciplinary teams; reported early full face procedures lasted on the order of 22 hours [13][16][14]. Donor and recipient are matched on parameters including blood type, tissue (HLA) type, biological sex, skin color, tone and texture, and approximate age and facial size, and logistical constraints such as proximity between the donor and the recipient's surgical facility apply [3].

Donor authorization and family considerations

Facial tissue is not part of the standard deceased-organ donor registry authorization, so recovery of a face requires specific, separate consent, typically granted by the donor's surviving family, and in some cases reflecting wishes the donor documented in advance [3][18]. In the United States, the OPTN and organ procurement organizations follow dedicated guidance for VCA deceased-donor authorization that addresses the distinct consent process for these tissues [18].

Because facial tissue is closely tied to identity and appearance, recovery raises concerns for donor families about the integrity and appearance of the body [19][20]. To address this, surgical teams use a mask, mold, or conformer that reproduces the donor's facial features so the body can be presented for funeral and viewing purposes, supporting the family's bereavement and respecting the donor's dignity [19][2]. Importantly, a recipient does not come to look like the donor: because the recipient's underlying bone structure differs, the result is a blend of the two, although certain skin features such as freckles, moles, or scars may be retained [3].

Immunosuppression and rejection

Face transplant recipients require lifelong immunosuppression to prevent rejection of the allograft [6][2]. A common regimen is triple immunosuppressive therapy combining tacrolimus, mycophenolate mofetil, and corticosteroids, typically after induction therapy, targeting the T-cell-mediated response that drives acute rejection [5][21]. The principles overlap with those described in transplant immunology, but the prominent skin component makes facial allografts especially prone to rejection episodes.

Acute rejection is monitored largely through the skin, which is accessible for direct inspection and biopsy. The standard method of diagnosing acute rejection is the skin biopsy graded by the Banff classification for skin-containing composite tissue allografts, which assigns grades 0 to IV based on the intensity and distribution of the inflammatory infiltrate; early rejection shows perivascular lymphocytic infiltrates in the dermis, predominantly T-cells [5][21]. Because skin biopsy carries some morbidity and the Banff grading is semiquantitative and subject to observer variability, additional and adjunctive approaches, including mucosal biopsies, sentinel flaps, and candidate biomarkers, have been studied to improve rejection detection [5][22]. Over the long term, chronic rejection, including antibody-mediated rejection and graft vasculopathy, can develop and is a leading cause of irreversible graft loss [9][23].

Functional and aesthetic outcomes

When successful, face transplantation can restore both appearance and function, with reported benefits across immunological, functional, psychological, and aesthetic domains [1][2]. Recipients can regain sensation and motor function over time, supporting improvements in breathing, eating, swallowing, speech, and facial expression, along with measurable gains in social reintegration and quality of life [1][6][7]. Outcomes are not uniform, and the degree of functional and aesthetic recovery varies with the extent of the graft, rejection history, and individual healing [1][9].

Complications, graft loss, deaths, and re-transplantation

Face transplantation carries substantial risks. Beyond acute and chronic rejection, recipients face the recognized complications of long-term immunosuppression, including serious infections, metabolic effects, and an increased risk of malignancy [17][2]. In one analysis of 48 face transplant procedures in 46 patients, adverse outcomes occurred in 14 cases (about 29 percent), including 7 allograft losses (about 15 percent), and 10 patient deaths (about 22 percent), with leading causes of death being infection, malignancy, non-adherence to immunosuppression, and suicide [15].

A separate review of the first 50 face transplants worldwide, covering procedures from November 2005 through September 2023 across 18 centers in 11 countries, reported estimated 5-year and 10-year graft survival of approximately 85 percent and 74 percent, respectively; during follow-up 6 transplants were lost and 10 patients died [8][9]. Among patients who lost a graft, re-transplantation has been performed: in that series 2 patients with lost grafts underwent re-transplantation, demonstrating that a failed facial allograft can, in selected cases, be replaced by a second transplant [8][9]. Loss of a facial allograft has been described by recipients as catastrophic, since it can return the same functional and aesthetic deficits that prompted the original transplant [23].

Ethics

Face transplantation raises distinctive ethical questions because, unlike most solid-organ transplants, it is generally not life-saving and is undertaken to improve quality of life while exposing the recipient to the lifelong risks of immunosuppression [6][24][20]. Commentators have framed the central tension as balancing significant, sometimes life-threatening risks against benefits that are primarily related to appearance, function, and psychosocial well-being [24][20].

Issues of identity and consent are prominent. The face is closely linked to personal identity and social recognition, raising questions about how a transplanted face affects the recipient's sense of self, even though the recipient does not assume the donor's appearance [19][3][20]. On the donor side, ethical attention focuses on voluntary and informed family consent, confidentiality, avoidance of coercion, and respect for the integrity and appearance of the donor's body [25][20]. Additional considerations include realistic informed consent given the experimental history of the field, equitable access, and the cost to the health system of a highly resource-intensive procedure requiring lifelong follow-up [25][24].

History

The first partial face transplant was performed on November 27, 2005, at Amiens University Hospital in Amiens, France, on Isabelle Dinoire, who had been severely disfigured in a dog attack [12][26]. The surgery, which transplanted the nose, lips, and chin from a deceased donor, was led by Bernard Devauchelle with Jean-Michel Dubernard [12][26].

The first face transplant in the United States was performed in December 2008 at the Cleveland Clinic by a team led by Maria Siemionow; the recipient, Connie Culp, had been disfigured by a shotgun blast, and roughly 80 percent of her face was replaced in an operation lasting about 22 hours [16][27]. The world's first full face transplant was performed in March 2010 at Vall d'Hebron University Hospital in Barcelona, Spain, by a team led by Joan Pere Barret; the operation replaced the patient's entire facial skin and musculature along with the nose, lips, jaws, cheekbones, palate, and teeth [13][14].

In the years that followed, additional centers in Europe, the United States, and elsewhere performed both partial and full procedures, and U.S. regulation formally brought VCAs, including faces, under OPTN oversight in 2014 [11][10]. By the time of a review covering procedures through September 2023, roughly 50 face transplants had been performed worldwide [8][9].

Current status

Face transplantation remains a specialized, low-volume procedure performed at a small number of experienced centers, with reported 5-year and 10-year graft survival estimates of approximately 85 percent and 74 percent in the published worldwide series (procedures through September 2023) [8][9]. It is established as a reconstructive option for select patients with extensive facial defects not amenable to conventional reconstruction, while ongoing work focuses on improving rejection monitoring, reducing the burden of immunosuppression, and refining patient selection and long-term management [5][1][17]. Because case counts and milestone figures continue to evolve, totals reported here should be re-confirmed against primary sources; the worldwide count of roughly 50 reflects procedures through September 2023 [8][9].

See also

• Vascularized composite allotransplantation (VCA)
• Hand transplantation
• Transplant immunology
• Organ transplantation

References

• Tasigiorgos S, et al. "Face Transplant: Indications, Outcomes, and Ethical Issues: Where Do We Stand?" J Clin Med (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC9571096/
• "Facial Transplantation: Complications, Outcomes, and Long-Term Management Strategies." PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC7759434/
• "Face Transplant: Surgery, How It Is Done & Rejection." Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/23281-face-transplant
• "Vascularized Composite Allotransplantation - an overview." ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/vascularized-composite-allotransplantation
• "A comparative analysis of lesional skin, sentinel flap, and mucosal biopsies in assessing acute face transplant rejection." Frontiers in Immunology / PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11997448/
• "Face Transplant Surgery." Cleveland Clinic (Reconstructive Transplantation). https://my.clevelandclinic.org/departments/dermatology-plastic-surgery/depts/reconstructive-transplantation/face-transplantation
• "Face Transplant: Indications, Outcomes, and Ethical Issues: Where Do We Stand?" MDPI, J Clin Med. https://www.mdpi.com/2077-0383/11/19/5750
• "An Update on the Survival of the First 50 Face Transplants Worldwide." PubMed. https://pubmed.ncbi.nlm.nih.gov/39292472/
• "18 years of face transplantation: Adverse outcomes and challenges." J Plast Reconstr Aesthet Surg. https://www.jprasurg.com/article/S1748-6815(23)00540-5/fulltext
• "Resources by organ type - vascular composite allograft." OPTN/HRSA. https://optn.transplant.hrsa.gov/professionals/by-organ/vascular-composite-allograft/
• "Organ Procurement and Transplantation Network." Federal Register (2013). https://www.federalregister.gov/documents/2013/07/03/2013-15731/organ-procurement-and-transplantation-network
• "First successful partial face transplant." Guinness World Records. https://www.guinnessworldrecords.com/world-records/first-successful-partial-face-transplant
• "Spanish hospital claims first full-face transplant." Medical Xpress. https://medicalxpress.com/news/2010-04-spanish-hospital-full-face-transplant.html
• "Spanish doctors conduct full face transplant." CNN. https://edition.cnn.com/2010/HEALTH/04/24/spain.face.transplant/index.html
• "18 years of face transplantation: Adverse outcomes and challenges." ScienceDirect. https://www.sciencedirect.com/science/article/pii/S1748681523005405
• "First U.S. face transplant performed." Deseret News. https://www.deseret.com/2008/12/17/20291781/first-u-s-face-transplant-performed/
• "Vascularized Composite Allotransplantation: Medical Complications." PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC7101879/
• "OPO guidance on VCA deceased donor authorization." OPTN/HRSA. https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/opo-guidance-on-vca-deceased-donor-authorization/
• "Cultural Perspectives in Facial Allotransplantation." PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3427025/
• "Facing the Future." Harvard Medical School Center for Bioethics. https://bioethics.hms.harvard.edu/journal/face-transplant-ethics
• "Increased levels of circulating MMP3 correlate with severe rejection in face transplantation." Scientific Reports (Nature). https://www.nature.com/articles/s41598-018-33272-7
• "Evolving Concepts of Skin and Mucosal Biopsy in Facial Vascularized Composite Allotransplantation." Current Transplantation Reports (Springer). https://link.springer.com/article/10.1007/s40472-014-0023-8
• "Face transplantation: A longitudinal histological study focusing on chronic active and mucosal rejection in a series with long-term follow-up." American Journal of Transplantation / ScienceDirect. https://www.sciencedirect.com/science/article/pii/S1600613522087172
• "Ethical Issues in Face Transplantation." AMA Journal of Ethics. https://journalofethics.ama-assn.org/article/ethical-issues-face-transplantation/2010-05
• "Ethics of facial transplantation revisited." PubMed. https://pubmed.ncbi.nlm.nih.gov/24565957/
• "Woman who received world's first face transplant, Isabelle Dinoire, dies." CBS News. https://www.cbsnews.com/news/frenchwoman-who-received-worlds-1st-face-transplant-isabelle-dinoire-dies/
• "Maria Siemionow." UIC Today. https://today.uic.edu/experts/maria-siemionow/